At Alcon, our surgical medical device products, such as the Hydrus® Microstent, are designed, manufactured and marketed with a body of science developed through rigorous bench research and clinical studies. As the body of knowledge behind Alcon’s products grows, so does the challenge of making our customers aware of its depth. Our medical affairs organization is thus focused on both high-quality data generation and its communication to the clinical community. High-quality scientific publications are essential to convey the clinical community’s knowledge and experience with the latest technology. This clinical science compendium provides a consolidated view of peer- reviewed publications for Hydrus ® Microstent, a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for adult primary open-angle glaucoma patients by reestablishing flow through Schlemm’s canal, the eye’s natural outflow pathway. In January 2022, Alcon Vision, LLC acquired Ivantis, Inc., the developer of Hydrus®